Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jointown Pharmaceutical Group CoSHSE:600998 +1.99%81 Return-on-Tangible-Equity is 11.78% as of Mar. 2026, which is 15% above its 10-year median of 10.24. GuruFocus rates SHSE:600998 with a GF Score™ of 81/100 and a GF Value™ of ¥5.58 (Fairly Valued). The stock has 6 warning signs investors should review. Among 112 Medical Distribution companies, Jointown Pharmaceutical Group Co ranks worse than 52.68% on this metric.
The historical rank and industry rank for Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600998'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.86 Med: 10.24 Max: 17.48
Current: 8.12
During the past 13 years, Jointown Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 17.48%. The lowest was 7.86%. And the median was 10.24%.
SHSE:600998's Return-on-Tangible-Equity is ranked worse than 52.68% of 112
companies
in the Medical Distribution industry
Industry Median: 8.755
vs SHSE:600998: 8.12
Jointown Pharmaceutical Group Co (SHSE:600998) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jointown Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms
Jointown Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jointown Pharmaceutical Group Co Return-on-Tangible-Equity Chart
SHSE:600998 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jointown Pharmaceutical Group Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.78% mean?
Jointown Pharmaceutical Group Co (SHSE:600998) has a Return-on-Tangible-Equity of 11.78% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jointown Pharmaceutical Group Co and its competitors. This is 15% above median its historical median of 10.24. Over the past decade, Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity has ranged from 7.86 to 17.48. According to the industry distribution chart, Jointown Pharmaceutical Group Co ranks #59 out of 112 companies in the Medical Distribution industry, placing it in the top 52.7%.
Is Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity too high?
Jointown Pharmaceutical Group Co's current Return-on-Tangible-Equity of 11.78% is 15% above median its 10-year median of 10.24. Over the past 10 years, this metric has ranged from a low of 7.86 to a high of 17.48. The Medical Distribution industry median Return-on-Tangible-Equity is 8.76. Jointown Pharmaceutical Group Co's value of 11.78% is 34.6% above this industry median. Based on the distribution chart, Jointown Pharmaceutical Group Co ranks #59 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Jointown Pharmaceutical Group Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jointown Pharmaceutical Group Co's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Jointown Pharmaceutical Group Co ranks #59 out of 112 companies for Return-on-Tangible-Equity. This places Jointown Pharmaceutical Group Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.76. Jointown Pharmaceutical Group Co's value of 11.78% is 34.6% above this benchmark. Historically, Jointown Pharmaceutical Group Co's own Return-on-Tangible-Equity has ranged from 7.86 to 17.48 over the past decade. While the company's 10-year median is 10.24 vs. the industry median of 8.76, Jointown Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.76, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jointown Pharmaceutical Group Co's current Return-on-Tangible-Equity of 11.78% is 34.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jointown Pharmaceutical Group Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jointown Pharmaceutical Group Co's current Return-on-Tangible-Equity is 11.78%, which is 15% above median its own 10-year median of 10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jointown Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jointown Pharmaceutical Group Co (SHSE:600998) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.58, compared to a current price of ¥5.12 — trading 8.2% below its estimated fair value. The current Return-on-Tangible-Equity is 11.78%, which is 15% above median its 10-year median of 10.24 and 34.6% above the Medical Distribution industry median of 8.76. Jointown Pharmaceutical Group Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jointown Pharmaceutical Group Co (SHSE:600998), the current Return-on-Tangible-Equity is 11.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jointown Pharmaceutical Group Co (SHSE:600998) Overvalued in 2026?
Based on GuruFocus' analysis, Jointown Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥5.12 is trading 8.2% below its estimated GF Value™ of ¥5.58.
GuruFocus considers Jointown Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600998:
Return-on-Tangible-Equity: 11.78% (15% above median its 10-year median of 10.24)
GF Value™: ¥5.58 vs. price of ¥5.12 (8.2% below fair value)
Industry Position: 34.6% above the Medical Distribution median (#59 of 112)
No single metric tells the full story. See the SHSE:600998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jointown Pharmaceutical Group Co Business Description
Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and mainly serves medical institutions, wholesale enterprises, and retail pharmacies.
81GF Score
Get the complete analysis for SHSE:600998
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600998 has been successfully added to your 
